Investor Information

Investor Information

Printer Icon
Font Decrease Icon
Font Increase Icon

Investor Information

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products company that develops, markets, and sells consumer health products globally. Our focus is the dietary supplement and functional food market segments.

The Bioxyne team has extensive skills and knowledge in developing and commercialising life sciences, health and medical technologies. The Bioxyne Board and Management, backed by a supportive shareholder base, is positioned to pursue new growth opportunities for our products in Australia, Asia and beyond.

Bioxyne is currently selling PCC® to Nu-Skin Enterprises (USA) as the active ingredient in ProBio PCC™, and PCC® is being used in a number of other products currently sold in Europe and North America.

Bioxyne sells its own PCC®-based products: Progastrim® for gut and immune health, proTract® for atopic dermatitis in infants and Progastrim® + Vitamin C for cold symptoms on-line in Australia and China, and shortly will be available in Australian pharmacies.

Probiotic PCC®

Bioxyne’s proprietary and clinically tested probiotic is Lactobacillus fermentum VRI-003 (PCC®). PCC® is supported by several clinical trials which describe its ability to boost immune and gastrointestinal health. The probiotic development is supported by a manufacturing agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of probiotics and other dietary supplement products for the food, health, pharmaceutical and agriculture industries.

Bioxyne’s probiotic sales are led by ProBio PCC™, a probiotic product containing PCC® sold globally exclusively by Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who offers only quality solutions to their customers.

Bioxyne sells its own branded PCC®-containing products in Australia: Progastrim® for gut and immune health and proTract® for atopic dermatitis (eczema).

Bioxyne is actively pursuing new opportunities in the immune health sector that will enhance future value for its shareholders. These include further clinical studies to develop new products to expand product range and to support the marketing of current products.

Global Treasure New Zealand

In April 2017, Bioxyne acquired a New Zealand-based product development and sales business, Global Treasure New Zealand (GTNZ). GTNZ’s current products include two functional food products (BK18 and Allura), a skincare product (Bessence) and a product for joint health, Arthroflex.